Benefit-risk profile in P2X3 receptor antagonists for treatment of chronic cough: Dose-response model-based network meta-analysis
Not Applicable
- Conditions
- Refractory chronic cough Unexplained chronic cough
- Registration Number
- JPRN-UMIN000050622
- Lead Sponsor
- Tokai University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
We excluded studies that compared P2X3 receptor antagonists with any other active treatment, as well as animal trials, abstracts, and any study designs other than RCTs.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcomes were the 24-hour cough frequency and the incidence of taste disturbances. The efficacy outcomes comprised the 24-h cough frequency (coughs per hour), evaluated as a percentage change from baseline, where a reduction indicated improvement. The minimum important difference (MID) was considered a 20% reduction. Taste disturbances with MIDs of 15 in absolute risk difference per 100 patients.
- Secondary Outcome Measures
Name Time Method